PARATEK PHARMACEUTICALS, INC.

75 Park Plaza

Boston, Massachusetts 02116

(617) 807-6600

July 7, 2020

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

 

RE: Paratek Pharmaceuticals, Inc.

        Registration Statement on Form S-3, as amended (File No. 333-238150)

        Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date of its Registration Statement on Form S-3, as amended (File No. 333-238150) (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that it will be declared effective at 4:00 p.m. Eastern Time on July 9, 2020, or as soon as possible thereafter. The Company hereby authorizes Thomas J. Danielski of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

It would be appreciated if, as soon as the Registration Statement is declared effective, you would inform Thomas J. Danielski of Ropes & Gray LLP at thomas.danielski@ropesgray.com or (617) 235-4961.

 

 

 

Very truly yours,

 

PARATEK PHARMACEUTICALS, INC.

 

 

By:

 

/s/ William M. Haskel

 

 

William M. Haskel

 

 

Senior Vice President, General Counsel and Corporate Secretary